Epigenetic Modifications in Cancer Progression: Implications for Novel Therapeutic Targets
1Muhammad Khurrum Islam, 2Samah Badr Hamad, 3Mobeen Ali, 4Babar Shahzad, 5Umar Khan, 6Kamran Safdar
Submission: 08 December 2025 | Acceptance: 16 January 2026 | Publication: 16 February 2026
1Assistant Professor Of Oncology Sargodha Medical College / Doctor Faisal Masood Teaching Hospital, Sargodha.
2RAK College of Medicine, RAK Medical and Health Sciences University, UAE
Department of Biochemistry and Pathology
3PIMS
4PIMS Islamabad
5PIMS
6UHS Lahore
Background: Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNAs, play a pivotal role in cancer progression. These reversible changes influence gene expression without altering the DNA sequence and are increasingly recognized as key drivers of oncogenesis. Despite advancements in cancer therapy, targeting epigenetic mechanisms holds promise for developing novel therapeutic strategies.
Aim: This study aimed to evaluate the role of epigenetic modifications in cancer progression and to explore their potential as novel therapeutic targets.
Methods: This observational study was conducted at Fauji Foundation Hospital from October 2023 to September 2024, involving 80 participants diagnosed with various types of cancer. Epigenetic markers, including DNA methylation levels, histone acetylation, and expression profiles of non-coding RNAs, were analyzed using blood and tissue samples. Quantitative PCR, chromatin immunoprecipitation assays, and sequencing techniques were employed to identify and validate epigenetic alterations.
Results: Significant alterations in DNA methylation patterns were observed in tumor suppressor and oncogene regions across multiple cancer types. Increased histone acetylation was strongly associated with aggressive tumor phenotypes. Dysregulated non-coding RNAs were identified, with certain microRNAs demonstrating tumor-promoting or tumor-suppressing properties. Correlation analyses revealed that specific epigenetic changes were linked to disease stage and prognosis. Importantly, in vitro experiments demonstrated that epigenetic modulators, including DNA methyltransferase inhibitors and histone deacetylase inhibitors, effectively suppressed cancer cell proliferation and induced apoptosis.
Conclusion: The study highlighted the critical role of epigenetic modifications in cancer progression and identified several promising therapeutic targets. Epigenetic therapies, when used alone or in combination with conventional treatments, have the potential to improve outcomes for cancer patients. These findings underscore the need for further research to translate epigenetic discoveries into clinical applications.
Keywords: Epigenetics, Cancer progression, DNA methylation, Histone modifications, Non-coding RNAs, Therapeutic targets, Fauji Foundation Hospital.